PSMB10
ENSG00000205220
Target class
Enzyme
Chromosome
16
Approved drugs
3
Clinical candidates (approved and in development)
6
- Approved drugs
- 3
- ClinGen gene-disease validity
- Limited
- Clinical candidates (approved and in development)
- 6
- Chemical probe available
- No
- Target name
- PSMB10
- Gene name
- Proteasome 20S subunit beta 10
- Gene symbol
- PSMB10
- Previous gene symbols
- MECL1
- Protein name
- Proteasome subunit beta type-10 (EC 3.4.25.1) (Low molecular mass protein 10) (Macropain subunit MECl-1) (Multicatalytic endopeptidase complex subunit MECl-1) (Proteasome MECl-1) (Proteasome subunit beta-2i)
- LMP10
- MGC1665
- beta2i
- Gene biotype
- Protein coding
- Gene family
- Proteasome
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 302.52
- Tissue specificity (Gini)
- 0.3
- Tissue specificity (tau)
- 0.831
- KEGG gene identifiers
- hsa:5699
- Protein interaction confidence
- 0.897482
- Protein interaction partners
- 56
- R-HSA-1236974
- R-HSA-1236978
- R-HSA-9907900
- R-HSA-9912633
- End position
- 67936864
- Start position
- 67934506
- Chromosome
- 16
- Strand
- Reverse
- Cytoplasm . Nucleus .
- Cytosol
- Vesicles
- Tissue specificity (tau)
- 0.831486
- Expression inequality (Gini)
- 0.300187
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes
- 302.52
- Spleen
- 186.4
- Whole Blood
- 148.48
- Small Intestine - Terminal Ileum
- 126.35
- Lung
- 94.22
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes302.52
- Spleen186.4
- Whole Blood148.48
- Small Intestine - Terminal Ileum126.35
- Lung94.22
- Colon - Transverse79.26
- Bladder67.89
- Prostate67.07
- Cervix - Endocervix62.36
- Thyroid56.43
- Ovary55.79
- Minor Salivary Gland55.71
- Adipose - Subcutaneous55.58
- Colon - Sigmoid55.52
- Adipose - Visceral (Omentum)54.13
- Breast - Mammary Tissue53.87
- Uterus51.38
- Fallopian Tube50.26
- Adrenal Gland50.19
- Kidney - Medulla48.51
- Brain - Nucleus accumbens (basal ganglia)48.37
- Vagina47.74
- Brain - Caudate (basal ganglia)47.68
- Brain - Substantia nigra47.32
- Nerve - Tibial47.31
And 29 more, listed on the interactive page.
- GO:0002479
- GO:0006959
- GO:0010499
- GO:0000502
- GO:0005829
- GO:0004175
- GO:0005515
Related records
Trials (799)
- 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
- 3D PET Myocardial Blood Flow and Rb82 Infusion Profiles
- 4SCAR-T Therapy Post CD19-targeted Immunotherapy
- A Basket Study of CTA313 in Participants With Active Autoimmune Diseases
- A Clinical Research About CD70-targeted CAR-NKT Cells Therapy Advanced Malignant Solid Tumors
- A Clinical Study Evaluating the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Three or More Lines of Treatment
- A Clinical Study of BioTTT001 in Combination With SOX and Toripalimab in Patients With Gastric Cancer
- A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer
- A Clinical Study of CD19 CAR-T in Active Systemic Lupus Erythematosus
- A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors
- A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer
- A Clinical Study on the Safety, Tolerance, and Preliminary Efficacy of γδ-T Cell Injection in the Treatment of Advanced Bladder Cancer
- A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
- A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
- A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis
- A First in Human Study to Evaluate the Safety of Infusion of MNV-BM-PLC (Autologous CD34+ Cells Enriched With Placenta Derived Allogeneic Mitochondria) in Patients With Primary Mitochondrial Diseases Associated With Mitochondrial DNA Mutation or Deletion
- A Hypoxia-Inducible CAR-T Cell Targeting AXL and CD73 for Advanced Gastric Cancer
- A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."
- A Multi-cohort Study of Safety, Efficacy, PK and PD of GNR-055 in Patients With Mucopolysaccharidosis Type II
- A Multi-site Study of Autologous Cord Blood Cells for Hypoxic Ischemic Encephalopathy
Drugs (6)
- Bortezomib D-mannitol 26S proteasome inhibitor
- Carfilzomib 26S proteasome inhibitor
- Ixazomib 26S proteasome inhibitor
- Ixazomib citrate 26S proteasome inhibitor
- Marizomib 20S proteasome inhibitor
- Oprozomib 26S proteasome inhibitor